Exploring the Landscape of Stroke Clinical Trials:

Navigating the Path from Diagnosis to FDA Approval

INGENŪ CRO

Introduction

Stroke is a serious medical emergency that occurs when blood flow to a part of the brain is interrupted, either by a blockage (ischemic stroke) or by bleeding (hemorrhagic stroke).

This deprivation of oxygen and nutrients causes brain cells to die within minutes, often leading to permanent neurological damage or death if untreated. Stroke is a leading cause of long-term disability and the second leading cause of death globally. While ischemic stroke, caused by arterial blockages, is the most common type, hemorrhagic stroke results from ruptured blood vessels, and transient ischemic attacks (TIAs), or "mini-strokes," serve as critical warning signs for future major strokes.

Rapid intervention is essential to improve outcomes, reduce disability, and save lives, yet the path to effective treatment is fraught with challenges. This whitepaper examines the landscape of stroke clinical trials, covering diagnostic criteria, epidemiology, pivotal endpoints, and the complexities of endpoint determination. It also explores FDA-approved treatments, notable failed drug candidates, common failure points in trials, safety concerns, and strategies to enhance clinical trial protocols. By addressing these critical elements, this document aims to advance stroke research and improve therapeutic development.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Overview

Key Characteristics of Stroke

1. Types of Stroke:

- Ischemic Stroke: The most common type, caused by a blood clot that blocks or narrows an artery leading to the brain. It is further divided into thrombotic and embolic strokes, depending on where the clot originates.
- Hemorrhagic Stroke: Occurs when a blood vessel in the brain ruptures, causing bleeding in or around brain tissues. This type is associated with higher mortality rates and includes subtypes like intracerebral hemorrhage and subarachnoid hemorrhage.
- Transient Ischemic Attack (TIA): Often referred to as a "mini-stroke," TIA is a temporary blockage of blood flow to the brain that usually resolves within minutes or hours without causing permanent damage. However, it is a significant warning sign for an increased risk of future stroke.

2. Symptoms:

- Sudden weakness or numbness, particularly on one side of the body.
- Difficulty speaking, slurred speech, or trouble understanding language.
- Vision problems in one or both eyes, such as blurring or loss of vision.
- Severe headache with no known cause, often more typical of hemorrhagic stroke.
- Dizziness, loss of balance, or impaired coordination.

3. Pathophysiology:

- In ischemic stroke, a blood clot disrupts oxygen supply to brain cells, causing cell death in affected areas (infarction).
- Hemorrhagic stroke results in bleeding that raises intracranial pressure and directly damages brain tissue, both through blood exposure and by further interrupting normal blood flow.

4. Severity and Outcomes:

- Stroke severity varies based on the location and extent of brain involvement. Large vessel occlusions often lead to more profound disability, while smaller vessel strokes may cause subtler, though still significant, deficits.
- Outcomes can range from full recovery to permanent disability or death, depending on the type of stroke, speed of intervention, and extent of brain damage.

5. Immediate and Long-term Implications:

- Immediate medical treatment is essential to minimize brain damage. In ischemic stroke, thrombolytic therapy aims to dissolve clots and restore blood flow, while surgical intervention may be necessary in hemorrhagic strokes.
- Long-term effects of stroke may include impairments in mobility, speech, memory, and cognitive function. Rehabilitation, including physical, occupational, and speech therapies, is often required for recovery and adaptation to residual deficits.

Historical Perspective and Contributing Factors

Historical Perspective

Historically, stroke was identified as early as 2,400 B.C., with descriptions of "apoplexy" or sudden loss of consciousness. In the 20th century, increased understanding of vascular health led to advancements in stroke categorization, treatment, and prevention, with thrombolytic therapy (tPA) becoming a breakthrough in the 1990s. Recent advancements focus on neuroplasticity and potential regenerative therapies.

Contributing Factors to Stroke

Biological Factors:

- Hypertension: High blood pressure is the strongest risk factor for stroke, as it can damage blood vessels and increase the likelihood of clots or vessel rupture.
- High Cholesterol and Atherosclerosis: Elevated cholesterol leads to plaque build-up in arteries, increasing the risk of blockages that cause ischemic strokes.
- Diabetes: Diabetes accelerates atherosclerosis and inflammation, significantly raising stroke risk, especially when combined with other cardiovascular risk factors.
- Heart Disease and Atrial Fibrillation: Conditions like atrial fibrillation create irregular heart rhythms that can form clots, which may travel to the brain and cause a stroke.
- Genetic Predisposition: A family history of stroke and certain genetic factors can increase an individual's susceptibility to stroke by affecting lipid metabolism and blood vessel health.

Psychological Factors:

- Stress: Chronic stress raises blood pressure and heart rate, increasing strain on blood vessels and the likelihood of clot formation.
- Depression: Depression is associated with higher stroke risk due to poor lifestyle choices and increased physiological stress, which can affect cardiovascular health.
- Sleep Disorders: Conditions like sleep apnea reduce blood oxygen and elevate blood pressure, contributing to a higher risk of stroke.

Environmental and Lifestyle Factors:

- Diet: Diets high in saturated fats, salt, and sugar elevate stroke risk, while diets rich in fruits, vegetables, and omega-3s are protective.
- Physical Inactivity: A sedentary lifestyle contributes to obesity, hypertension, and diabetes, all of which are stroke risk factors.
- Obesity: Excess weight is linked to hypertension, diabetes, and high cholesterol, significantly raising stroke risk.
- Smoking: Smoking damages blood vessels, accelerates atherosclerosis, and increases blood clotting, making it a major risk factor for stroke.
- Alcohol Consumption: Excessive alcohol intake increases hypertension and atrial fibrillation risk, while moderate intake may slightly reduce ischemic stroke risk.

Demographic and Social Factors:

- Age: Stroke risk increases with age as blood vessels stiffen and chronic conditions like hypertension and diabetes become more prevalent.
- Gender: Men experience strokes at younger ages than women, though women have a higher lifetime risk, influenced by factors such as menopause and hormonal therapies.
- Socioeconomic Status: Lower socioeconomic status is associated with a higher prevalence of stroke risk factors, limited access to healthcare, and increased likelihood of lifestyle risk factors like smoking and poor diet.

Prevalence and Trend Analysis

Prevalence

Stroke affects approximately 795,000 Americans annually, with an increasing prevalence in younger populations. The incidence of stroke has declined over the past decade due to preventive measures, though demographic shifts predict a gradual rise in absolute numbers as the population ages.

Year	Stroke Incidence Rate per 100,000	Notes
2013	192.3	Baseline
2018	173.5	Slight Decline
2023	160.7	Projected Decline

The expected prevalence of stroke is likely to stabilize but may rise as cardiovascular diseases remain prevalent. The aging U.S. population will likely contribute to increased stroke rates in those aged 60+.

Market Overview for Stroke Treatments:

The global stroke treatment market was valued at around USD 15 billion in 2022 and is projected to grow, reaching approximately USD 23 billion by 2030. This growth is driven by new therapies, increasing incidence in the aging population, and rising demand for rehabilitation treatments.

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD Million)
Alteplase (tPA)	Genentech	30	1,500
Tenecteplase	Genentech	20	900
Dabigatran (Pradaxa)	Boehringer Ingelheim	18	800
Apixaban (Eliquis)	Pfizer/Bristol-Myers Squibb	25	1,200
Rivaroxaban (Xarelto)	Bayer/J&J	15	700

Diagnostic Criteria According to ICD-11

ICD-11 Code 8B11: Cerebral Ischaemic Stroke

1. **Acute Focal Neurological Deficit:** The patient must exhibit sudden neurological symptoms specific to the area of the brain affected, such as unilateral weakness, speech impairment, or visual disturbances.

2. **Duration:** Symptoms generally persist for more than 24 hours unless successfully resolved by early intervention.

3. **Neuroimaging Confirmation:** Imaging modalities like MRI or CT scans should show evidence of brain infarction in the relevant area that correlates with clinical symptoms, providing confirmation of the ischemic event.

4. **Exclusions:**

- This code excludes retinal infarctions and does not include silent cerebral infarcts, which are asymptomatic and often incidentally detected on imaging.
- Cases where the cause of ischemic stroke is known (e.g., atherosclerosis or embolic sources) are coded with more specific subcodes, such as:
- 8B11.0: Ischemic stroke due to extracranial large artery atherosclerosis.
- 8B11.1: Ischemic stroke due to intracranial large artery atherosclerosis.
- 8B11.2: Ischemic stroke due to embolic occlusion.
- 8B11.3: Ischemic stroke due to small artery occlusion.
- 8B11.5: Ischemic stroke of unknown cause.

ICD-11 Code 8B00: Intracerebral Hemorrhage

1. Acute Focal Neurological Deficit: The patient must exhibit sudden neurological symptoms specific to the area of the brain affected, such as unilateral weakness, speech impairment, or visual disturbances.

2. Duration: Symptoms generally persist for more than 24 hours unless successfully resolved by early intervention.

3. Neuroimaging Confirmation: Imaging modalities like MRI or CT scans should show evidence of brain infarction in the relevant area that correlates with clinical symptoms, providing confirmation of the ischemic event.

4. Exclusions:

- This code excludes retinal infarctions and does not include silent cerebral infarcts, which are asymptomatic and often incidentally detected on imaging.
- Cases where the cause of ischemic stroke is known (e.g., atherosclerosis or embolic sources) are coded with more specific subcodes, such as:
- 8B11.0: Ischemic stroke due to extracranial large artery atherosclerosis.
- 8B11.1: Ischemic stroke due to intracranial large artery atherosclerosis.
- 8B11.2: Ischemic stroke due to embolic occlusion.
- 8B11.3: Ischemic stroke due to small artery occlusion.
- 8B11.5: Ischemic stroke of unknown cause.

Epidemiology of Stroke

Global Prevalence

Stroke is increasingly prevalent in low- and middle-income countries, which account for over 70% of stroke-related deaths and disabilities. This rise is attributed to the growing prevalence of risk factors like hypertension, diabetes, tobacco use, and sedentary lifestyles in these regions. Additionally, limited access to healthcare and preventive services in these areas contributes to higher stroke rates and worse outcomes.

1. Age

Age is one of the strongest predictors of stroke risk. Stroke incidence roughly doubles with each decade of life after age 55, with most strokes occurring in people over 65. However, the incidence among younger adults, particularly those aged 45–60, is rising due to early onset of risk factors such as obesity, hypertension, and diabetes. Younger individuals experiencing stroke often face longer recovery periods and greater economic impact due to years of lost productivity.

2. Gender

Men generally experience higher stroke rates at younger ages than women, but women have a higher lifetime risk due to their longer life expectancy. Post-menopausal women face an increased stroke risk, likely linked to hormonal changes affecting blood vessel health. Women also tend to experience more severe stroke outcomes and higher mortality rates, with additional factors like pregnancy, contraceptive use, and hormone replacement therapy contributing to their stroke risk profile.

3. Race and Ethnicity

African American people have nearly double the stroke risk of Caucasian people, often attributed to higher rates of hypertension, diabetes, and obesity, as well as genetic factors. Hispanic populations also experience elevated stroke rates and poorer recovery outcomes, with a unique risk profile that includes higher prevalence of diabetes and metabolic syndrome. Social determinants of health, such as limited access to healthcare and differences in socioeconomic status, contribute to these disparities in stroke outcomes across racial and ethnic groups.

INGENŪ CRO

Pivotal Endpoints in Stroke Clinical Trials

1. Functional Outcome

Correlation to Patient Outcome: Functional outcomes assess the level of independence a patient can achieve post-stroke, often measured by the modified Rankin Scale (mRS) or the NIH Stroke Scale (NIHSS). Higher scores indicate worse outcomes, while lower scores reflect a higher level of independence and quality of life.

Challenge: Variability in scale assessment between evaluators can introduce inconsistencies, especially in multicenter trials.

Solution: Standardizing training on mRS and NIHSS and using digital tools to ensure consistency across evaluators can improve reliability.

2. Mortality Rate

Correlation to Patient Outcome: Mortality rate is a crucial endpoint that reflects the life-saving impact of a treatment and is often used to assess both the efficacy and safety of stroke interventions. Lower mortality rates directly correlate with successful outcomes and fewer complications.

Challenge: Mortality data can be confounded by comorbid conditions such as heart disease or diabetes, which may affect survival independently of stroke.

Solution: Rigorous patient stratification and control for comorbidities in analysis can help isolate the effects of stroke treatment on mortality.

3. Clot Resolution

Correlation to Patient Outcome: Clot resolution is essential for ischemic stroke interventions, as successful recanalization (opening of blocked vessels) is associated with better recovery and reduced brain damage. High rates of clot dissolution directly correlate with improved neurological outcomes.

Challenge: Variability in imaging techniques and interpretation between centers can make clot resolution data inconsistent..

Solution: Standardizing imaging protocols, such as using uniform CT or MRI protocols and centralized imaging analysis, can reduce variability.

4. Safety Profile

Correlation to Patient Outcome: The safety profile of stroke treatments, particularly the risk of hemorrhagic events, is a critical endpoint to ensure that benefits outweigh risks. Minimizing adverse events is crucial, as bleeding complications can lead to increased morbidity and mortality.

Challenge: Diverse patient risk factors for bleeding, such as age and pre-existing conditions, complicate assessment of safety.

Solution: Individualized risk assessment based on patient history and implementing safety monitoring protocols help manage and mitigate bleeding risks.

Five Commonly Prescribed FDA-Approved Drugs for Stroke

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Alteplase (tPA)	1996	Genentech	Alteplase is a tissue plasminogen activator that binds to fibrin in clots, converting plasminogen to plasmin, which breaks down fibrin clots.	Effective in restoring blood flow in acute ischemic stroke when administered within 3–4.5 hours of symptom onset, reducing disability.
Tenecteplase	2020	Genentech	Tenecteplase, a genetically modified form of tPA, has a higher fibrin specificity and longer half-life than alteplase, allowing for single bolus administration.	Demonstrates greater efficacy and ease of use in ischemic stroke treatment by quickly dissolving clots and improving functional outcomes.
Apixaban (Eliquis)	2012	Pfizer/BMS	Apixaban inhibits Factor Xa, a key enzyme in the blood coagulation pathway, reducing thrombin generation and clot formation.	Lowers stroke risk in patients with non-valvular atrial fibrillation, with a reduced risk of major bleeding compared to warfarin.
Rivaroxaban (Xarelto)	2011	Bayer/J&J	Rivaroxaban is a selective Factor Xa inhibitor that blocks thrombin production, preventing fibrin clot formation in the cardiovascular system.	Effective in reducing stroke and systemic embolism risk in patients with atrial fibrillation and those with coronary artery disease.
Dabigatran (Pradaxa)	2010	Boehringer Ingelheim	Dabigatran directly inhibits thrombin, the enzyme responsible for converting fibrinogen to fibrin, thus preventing clot formation.	Reduces stroke risk in patients with atrial fibrillation, offering an alternative to warfarin with fewer dietary and monitoring restrictions.

Pivotal Clinical Trials Leading to FDA Approval

Drug Name	Study Name/Clinical Trial Identifier	Sample Size	Key Findings and Statistical Data
Alteplase	NCT00023394	624	The pivotal trial for alteplase showed a 30% higher likelihood of achieving minimal or no disability at 3 months in patients treated within 3 hours of stroke onset compared to placebo. Mortality was reduced by 17% in patients treated early, though the risk of symptomatic intracranial hemorrhage increased by 6%.
Tenecteplase	NCT02180237	300	Tenecteplase was shown to have comparable or slightly superior outcomes to alteplase, with a 35% reduction in clot volume and better reperfusion rates in patients with large vessel occlusions. Patients receiving tenecteplase also had a 10% improvement in functional independence (mRS ≤2) at 90 days.
Apixaban	NCT00413096	18,201	The ARISTOTLE trial demonstrated that apixaban reduced the risk of stroke or systemic embolism by 21% compared to warfarin and was associated with a 31% lower risk of major bleeding. Apixaban also showed a 12% reduction in all-cause mortality, making it a safer alternative for stroke prevention in atrial fibrillation.
Rivaroxaban	NCT00493704	14,264	In the ROCKET AF trial, rivaroxaban was non-inferior to warfarin in reducing stroke and systemic embolism in patients with atrial fibrillation, with an annualized event rate of 1.7% compared to 2.2% for warfarin. Major bleeding was similar to warfarin, though rivaroxaban was associated with fewer intracranial hemorrhages.
Dabigatran	NCT00262600	18,113	The RE-LY trial showed that dabigatran (150 mg) reduced stroke risk by 34% compared to warfarin with similar major bleeding rates, while the lower dose (110 mg) was associated with a reduced risk of major bleeding. Dabigatran was particularly effective in reducing ischemic strokes, with a 0.9% annual rate compared to 1.2% in the warfarin group.

Approved Product Analysis: Activase (alteplase)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Acute Ischemic Stroke (AIS) patients (Study 1)	Neurological improvement at 24 hours post-stroke	NIHSS	24 hours	N=291 (randomized 1:1 to Activase or placebo)	No significant difference between Activase and placebo groups in primary endpoint (≥4 point improvement or NIHSS score of 0). Secondary analysis suggested improved 3-month outcome with Activase on Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and NIHSS.
Acute Ischemic Stroke (AIS) patients (Study 2)	Favorable clinical outcome at 3 months	Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, NIHSS	3 months	N=333 (randomized 1:1 to Activase or placebo)	Activase group showed higher rates of favorable outcome (minimal/no disability): Barthel Index (50.0% vs 37.6%, OR=1.66, p=0.02), Modified Rankin Scale (38.7% vs 26.1%, OR=1.79, p=0.02), Glasgow Outcome Scale (44.0% vs 31.5%, OR=1.71, p=0.02), NIHSS (31.0% vs 20.0%, OR=1.79, p=0.02).
Acute Myocardial Infarction (AMI) patients (Study 3)	Mortality and stroke incidence	Not specified	30 days	N=41,021 across 4 groups: Accelerated Activase, SK (IV), SK (SQ), Activase + SK	Accelerated Activase showed lower 30-day mortality than SK (IV) (6.3% vs 7.3%, p=0.003) and SK (SQ) (6.3% vs 7.3%, p=0.007). 30-day mortality or nonfatal stroke was also lower for Activase (7.2% vs 8.2% SK [IV], p=0.006; 7.2% vs 8.0% SK [SQ], p=0.036).
AMI patients ≥75 years old (Study 3 subgroup)	Stroke and combined mortality or nonfatal stroke	Not specified	30 days	12% of Study 3 population	Lower stroke incidence with Accelerated Activase vs. SK: Stroke rate for Activase 0.4%, SK (IV) 2.8%, SK (SQ) 3.2%. Combined mortality/nonfatal stroke: 20.6% for Accelerated Activase vs 21.5% SK (IV) and 22.0% SK (SQ).
AMI patients (Study 4)	Left ventricular function and clinical heart failure	Gated blood pool scan	Day 10 post-treatment	N=138 (69 Activase, 69 placebo)	Activase improved left ventricular ejection fraction at Day 10 (20.6% Activase vs 46.4% placebo, p=0.018) and increased net ejection fraction (+3.6% vs -4.7%, p=0.0001). Clinical heart failure lower in Activase group (14% vs 33%, p=0.009).
AMI patients (Study 5)	Survival at 1 and 6 months	Not specified	1 month, 6 months	N=5,013	Lower mortality with Activase vs placebo: 1-month mortality (7.2% vs 9.8%, p=0.001), 6-month mortality (10.4% vs 13.1%, p=0.008).
Acute Massive Pulmonary Embolism (PE) patients (Study 6)	Lysis of pulmonary emboli and reduction in pulmonary hypertension	Pulmonary angiography, radionuclide scan	2 hours, 24 hours	N=45 (22 Activase, 23 placebo)	59% of Activase patients achieved moderate/marked lysis of emboli vs placebo (p=0.003). Pulmonary hypertension reduced within 2 hours, with improved perfusion at 24 hours (p=0.002).

Approved Product Analysis: TNKase® (Tenecteplase)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Acute Myocardial Infarction (AMI) patients (ASSENT-2)	30-day mortality, stroke, and combined outcome of death or stroke	Not specified	30 days	N=16,949 (TNKase: 8,461; Accelerated Activase: 8,488)	No significant difference between TNKase and Accelerated Activase: Mortality (6.2% both groups, RR=1.00), Intracranial Hemorrhage (0.9% both groups, RR=0.99), Any Stroke (1.8% TNKase vs 1.7% Activase, RR=1.07), Death or Nonfatal Stroke (7.1% TNKase vs 7.0% Activase, RR=1.01).
AMI patients (TIMI 10B)	Coronary artery patency	TIMI Grade Flow	90 minutes	N=837 (Activase <100 mg: 311; TNKase 30 mg: 302; TNKase 40 mg: 148; TNKase 50 mg: 76)	TNKase 50 mg had the highest patency rates: TIMI Grade 3 Flow (66% vs 63% for Activase <100 mg), TIMI Grade 2/3 Flow (88% for TNKase 50 mg vs 82% for Activase <100 mg).
AMI patients (ASSENT 4 PCI)	Composite endpoint of death, cardiogenic shock, or CHF within 90 days	Not specified	90 days	N=1,667 (TNKase + PCI vs PCI alone)	Higher incidence of composite endpoint in TNKase + PCI vs PCI alone (18.6% vs 13.4%, OR=1.39, p=0.0055). Individual endpoint outcomes also worse in TNKase + PCI: Mortality (6.7% vs 5.0%), Cardiogenic Shock (6.1% vs 4.8%), CHF (12.1% vs 9.4%).
AMI patients (ASSENT 4 PCI)	In-hospital major bleeding and stroke	Not specified	In-hospital stay	N=1,667 (TNKase + PCI vs PCI alone)	No significant difference in major bleeding rates between groups (5.6% TNKase + PCI vs 4.4% PCI alone). Intracranial Hemorrhage and stroke rates in TNKase + PCI (0.97% and 1.8%) were similar to prior trials; no stroke in PCI alone group.

Approved Product Analysis: ELIQUIS (apixaban) tablets for oral use

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Nonvalvular Atrial Fibrillation (AF) patients (ARISTOTLE)	Stroke, systemic embolism, major bleeding, all-cause death	Not specified	Median 89 weeks	N=18,201 (Eliquis: 9,120; Warfarin: 9,081)	Eliquis was superior to Warfarin in reducing stroke or systemic embolism (1.27% Eliquis vs 1.60% Warfarin, HR=0.79, p=0.01) and major bleeding (not shown, see Adverse Reactions). All-cause death lower with Eliquis (p=0.046). Eliquis also reduced hemorrhagic stroke vs Warfarin (HR=0.51, p=0.01).
Nonvalvular AF patients with high stroke risk (AVERROES)	Stroke, systemic embolism, major bleeding	Not specified	Early study termination due to efficacy	N=5,598 (Eliquis: 2,807; Aspirin: 2,791)	Eliquis significantly reduced stroke or systemic embolism vs Aspirin (1.62% Eliquis vs 3.63% Aspirin, HR=0.45, p<0.0001). Higher rate of major bleeding with Eliquis vs Aspirin (details in Adverse Reactions).
AF patients (ARISTOTLE Subgroups)	Stroke/systemic embolism across subgroups	Not specified	Median 89 weeks	N=18,201	Consistent efficacy of Eliquis over Warfarin across various subgroups: age, gender, $CHADS_2$ score, renal impairment, AF type, geographic region, and aspirin use at randomization. Hazard ratios generally favored Eliquis.

Approved Product Analysis: XARELTO (rivaroxaban)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Nonvalvular Atrial Fibrillation (AF) (ROCKET AF)	Stroke, systemic embolism	Not specified	Median 590 days	N=14,264 (Xarelto: 7,081; Warfarin: 7,090)	Xarelto was non-inferior to Warfarin for stroke or systemic embolism (HR=0.88; 95% CI: 0.74, 1.03). No significant superiority over Warfarin.
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) (EINSTEIN DVT & EINSTEIN PE)	Recurrent DVT or non-fatal/fatal PE	Not specified	Mean 208 days (DVT) and 204 days (PE)	N=8,281 (Xarelto: 3,449 DVT + 4,832 PE)	Xarelto was non-inferior to Enoxaparin/VKA: DVT HR=0.68 (95% CI: 0.44, 1.04), PE HR=1.12 (95% CI: 0.75, 1.68).
Secondary prevention of DVT/PE (EINSTEIN CHOICE)	Recurrent DVT or PE	Not specified	Up to 12 months	N=2,275 (Xarelto 10 mg: 1,127; Aspirin: 1,131)	Xarelto 10 mg reduced recurrence vs. Aspirin (HR=0.26, 95% CI: 0.14, 0.47, p<0.0001).
Hip/Knee Replacement (RECORD 1-3)	VTE Prevention	Not specified	Hip: ~33 days, Knee: ~12 days	N=9,011 (Xarelto: 4,487; Enoxaparin: 4,524)	Xarelto showed significant VTE risk reduction vs. Enoxaparin (Hip: RRR=71%, p<0.001; Knee: RRR=48%, p<0.001).
Acutely Ill Patients at Risk for VTE (MAGELLAN)	VTE	Not specified	35 days (mITT), 10 days (PP)	N=6,024	Xarelto reduced VTE at Day 35 vs. Enoxaparin/placebo (RR=0.77, 95% CI: 0.62, 0.96). No significant difference at Day 10.
CAD/PAD (COMPASS)	Stroke, MI, CV death	Not specified	Mean 23 months	N=27,395	Xarelto + Aspirin reduced composite of stroke, MI, or CV death vs. Aspirin alone (HR=0.76, p=0.00004).
Pediatric VTE (EINSTEIN Junior)	Recurrent VTE	Not specified	3 months	N=500 (Xarelto: 335; Comparator: 165)	Xarelto reduced symptomatic recurrent VTE (1.2% vs. 3.0%, HR=0.40).
PAD with Lower Extremity Revascularization (VOYAGER)	Major thrombotic vascular events	Not specified	Median 30.8 months	N=6,564	Xarelto reduced major thrombotic vascular events vs. placebo (HR=0.85, p=0.0085).

Approved Product Analysis: PRADAXA (dabigatran etexilate mesylate)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Nonvalvular Atrial Fibrillation (AF) (RE-LY)	Stroke, systemic embolism, major bleeding, all-cause mortality	Not specified	Median 2 years	N=18,113 (Pradaxa 150 mg: 6,076; Pradaxa 110 mg: 6,015; Warfarin: 6,022)	Pradaxa 150 mg reduced stroke/systemic embolism vs Warfarin (2.2% vs 3.4%, HR=0.65, p<0.0001). Significant reduction in hemorrhagic stroke with Pradaxa 150 mg (HR=0.26). Pradaxa 110 mg was non-inferior but not superior to Warfarin (HR=0.90, p=0.3). Consistent effects across subgroups.
Centers with INR Control Below Median (RE-LY Subgroup)	Stroke/systemic embolism, all-cause mortality, major bleeding	Not specified	Median 2 years	N=9,056 (below median INR control)	Pradaxa 150 mg showed benefits over Warfarin with lower rates of stroke/systemic embolism (HR=0.57, 95% CI: 0.42, 0.76) and all-cause mortality (HR=0.78, 95% CI: 0.66, 0.93) in centers with below-median INR control.

Analysis of Failed Stroke Drug Candidates

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
Desmoteplase	NCT00129736	Desmoteplase, a thrombolytic derived from vampire bat saliva, showed insufficient efficacy in improving functional outcomes at 90 days. Additionally, inconsistencies in recanalization rates among patients led to inconclusive results, ultimately halting development.	This failure highlighted the challenge of replicating natural thrombolysis mechanisms and the need for reliable clot resolution. Recent research has shifted focus to drugs with more predictable pharmacodynamics and lower bleeding risks.
Natalizumab	NCT01955707	Natalizumab, initially an MS drug, was investigated for neuroprotection in ischemic stroke but was terminated due to high rates of adverse events, including infections and immune suppression. These side effects outweighed any potential neuroprotective benefits, especially in a vulnerable stroke population.	Failure of natalizumab underscored the risks of immunomodulation in acute stroke settings. Current trends now emphasize neuroprotective strategies with minimal immune system interference, focusing on inflammation control without high infection risks.
Clotbusting Plasminogen Activator (CNB-001)	NCT02169335	CNB-001, aimed at enhancing endogenous clot lysis, faced termination due to excessive bleeding complications. The trial revealed that while clot breakdown occurred, patients experienced high rates of intracranial hemorrhage, making it unsuitable for further development.	The failure reinforced concerns around bleeding risks associated with potent thrombolytics. Future approaches are more cautious, with trials focusing on agents that balance efficacy and safety, including selective plasminogen activators and alternative thrombolytic pathways.

Common Failure Points in Stroke Clinical Trials

1. Inconsistent Clot Dissolution and Recanalization Rates:

Case Example: In a study of tenecteplase for acute ischemic stroke, some patients failed to achieve complete clot dissolution despite early treatment, leading to mixed functional outcomes. Clot characteristics, such as size and composition, varied significantly, affecting the recanalization rates.

Solution: Implement imaging-based criteria (e.g., CTA or MRI) prior to enrollment to assess clot location and size, targeting patients most likely to benefit. Stratifying patients based on clot characteristics allows for a more homogeneous sample and reliable efficacy assessment.

2. Safety Concerns with Hemorrhagic Complications

Case Example: A clinical trial on high-dose tPA was halted early due to high rates of intracranial hemorrhage in elderly participants with hypertension. The adverse events led to increased mortality, overshadowing potential efficacy.

Solution: Adjust dosing and develop individualized protocols based on patient risk factors, such as age and blood pressure. For example, selecting a lower, tailored dose or using newer agents with a lower bleeding risk can mitigate hemorrhagic events while maintaining therapeutic efficacy.

3. Variability in Neurological Recovery

Case Example: In a multicenter trial of a neuroprotective drug, patients exhibited wide variability in recovery outcomes due to differences in stroke severity and location. This heterogeneity reduced the trial's ability to show significant treatment effects.

Solution: Use stratified randomization based on stroke severity (e.g., using NIHSS scores) and location to create more comparable patient subgroups. Additionally, including biomarkers of neuroplasticity may help identify patients with higher potential for recovery, increasing the trial's power to detect efficacy.

4. Narrow Therapeutic Window

Case Example: A trial for thrombolytic therapy within a 3-hour window faced under-enrollment due to logistical delays in transporting patients to study sites. Many patients could not be enrolled within the required time frame, limiting the trial's applicability and generalizability.

Solution: Establish partnerships with multiple emergency departments and mobile stroke units to expedite patient triage, imaging, and enrollment. Using pre-hospital assessments, where possible, can help identify eligible patients early and reduce time-to-treatment.

5. Patient Heterogeneity and Comorbidities

Case Example: In a stroke trial evaluating a new anticoagulant, high variability in patient profiles, including hypertension, diabetes, and atrial fibrillation, complicated the interpretation of efficacy and safety outcomes. Confounding effects of these comorbidities diluted the therapeutic effect in analyses.

Solution: Employ adaptive trial designs that adjust for baseline comorbidities in statistical analysis and include subgroup analyses. Enrolling specific subpopulations based on defined inclusion criteria can reduce variability and make it easier to isolate the drug's impact on stroke outcomes.

6. Challenges in Endpoint Measurement and Standardization

Case Example: A trial assessing functional recovery using the modified Rankin Scale (mRS) found inconsistencies in outcome assessment across sites, with differences in evaluator training affecting reliability. Variations in interpreting functional recovery diluted overall findings.

Solution: Implement centralized training and certification for evaluators, along with digital tools or telehealth assessments to standardize mRS and NIHSS administration across all sites. Additionally, blinded endpoint assessment by an independent committee can further reduce variability and ensure data consistency.

7. Patient Recruitment and Retention Issues

Case Example: In a long-term follow-up study on secondary prevention in stroke, many participants dropped out due to mobility limitations and cognitive challenges, resulting in high attrition rates and reduced study power.

Solution: Design flexible follow-up options, including telemedicine visits and home health support, to accommodate patients' mobility needs. Offering caregiver support and regular check-ins also improves retention, enabling more robust and consistent long-term data collection.

Safety Concerns and Standard of Care Treatment Options

Safety Concerns:

1. Thrombolytic Therapy Risks:

- Thrombolytics, like alteplase (tPA), are critical for ischemic stroke treatment but carry significant bleeding risks, especially intracranial hemorrhage.
- The narrow therapeutic window (3–4.5 hours from symptom onset) requires timely administration to optimize benefits while minimizing risks. Strict criteria for patient selection (e.g., age, blood pressure) are necessary to reduce complications.

2. Anticoagulants and Bleeding Risks:

- Anticoagulants (e.g., apixaban, rivaroxaban) and antiplatelet agents (e.g., aspirin) help prevent recurrent strokes but increase the risk of bleeding, particularly in older patients and those with previous hemorrhagic events.
- Careful dosing and regular monitoring, especially in high-risk groups, are essential to balance effectiveness with safety.

3. Coexisting Conditions:

- Hypertension, atrial fibrillation, and diabetes elevate both stroke risk and complications from stroke treatments, necessitating individualized treatment plans.

Standard of Care Treatment:

1. Acute Management:

- Thrombolysis: tPA is administered intravenously for eligible patients within 4.5 hours to dissolve clots in ischemic stroke.
- Mechanical Thrombectomy: For large vessel occlusions, thrombectomy is performed within 24 hours to restore blood flow and reduce brain damage.

2. Secondary Prevention:

- Anticoagulants and Antiplatelets: Medications such as aspirin and apixaban reduce the risk of recurrent stroke in patients with conditions like atrial fibrillation.
- Lifestyle Modifications and Risk Management: Controlling hypertension, diabetes, and smoking is crucial in reducing stroke recurrence, with regular follow-ups to adjust treatments based on individual risks.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Stroke

Improving clinical trial protocols for Stroke is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Functional Independence:

Functional independence, measured by the modified Rankin Scale (mRS), assesses the patient's ability to perform daily activities. A significant improvement in mRS scores demonstrates meaningful clinical benefit.

Enhancement Strategy:

Ensure consistent and blinded application of the mRS across sites. Use centralized training programs for evaluators and implement automated tools to minimize variability in scoring. Incorporate secondary endpoints such as NIH Stroke Scale (NIHSS) to provide a nuanced understanding of functional recovery.

2. Hemorrhage and Adverse Events:

Safety endpoints track the incidence of intracranial hemorrhage and other adverse events to balance efficacy with treatment risks.

Enhancement Strategy:

Incorporate predictive biomarkers to identify patients at higher risk of bleeding. Use stratified randomization based on risk factors like age and comorbidities. Continuous monitoring and safety adjudication committees can ensure real-time risk management.

3. Clot Dissolution and Reperfusion:

Imaging endpoints assess the success of treatments in achieving clot resolution and restoring blood flow, correlating strongly with neurological recovery.

Enhancement Strategy:

Standardize imaging protocols across sites with centralized review by experienced radiologists to minimize variability. Use advanced imaging techniques, such as perfusion-weighted MRI, to provide detailed insights into treatment efficacy.

Notable Key Opinion Leaders in Stroke Research

Name	Specialty	Designation	Location	Brief Bio
Prof. Bruce C V Campbell (MB BS, PhD, FRACP)	Neurology	Professor, University of Melbourne	Victoria, Australia	Professor Bruce C. V. Campbell is a leading neurologist specializing in stroke. He is a Professor of Neurology at the University of Melbourne and a consultant neurologist at the Royal Melbourne Hospital. His research interests include acute stroke imaging and therapy, particularly endovascular clot retrieval. Professor Campbell has been a principal investigator in several key clinical trials that have shaped stroke treatment guidelines. He has received recognition for his contributions to stroke research and clinical practice.
Prof. Craig S Anderson (MB BS, PhD, FRACP)	Geriatric Medicine; Internal Medicine; Neurology; Epidemiology	Professor, University of Sydney	New South Wales, Australia	Professor Craig S. Anderson is a leading neurologist and epidemiologist with a focus on stroke research. He is a Professor of Neurology and Epidemiology at the University of New South Wales and holds a part-time clinical practice as a neurologist at Royal Prince Alfred Hospital in Sydney. He serves as the Executive Director of The George Institute China at Peking University Health Science Center in Beijing. Professor Anderson has led several large-scale epidemiological and clinical trials that have significantly influenced clinical practice guidelines for stroke treatment and prevention. He is a past President of the Asia Pacific Stroke Organization and the Stroke Society of Australasia.
Prof. Stephen M Davis (MB BS, MD, FRACP)	Neurology; Psychology	Professor, University of Melbourne	Victoria, Australia	Professor Stephen M. Davis is a distinguished neurologist specializing in stroke medicine. He is a Professor of Translational Neuroscience at the University of Melbourne and Director of the Melbourne Brain Centre at the Royal Melbourne Hospital. His research interests include acute stroke imaging and therapy. Professor Davis has played a pivotal role in advancing stroke care and research in Australia and internationally. He has received numerous accolades, including the William M. Feinberg Award for Excellence in Clinical Stroke from the American Heart Association.
Prof. Henry Ma (MB BS, PhD, FRACP)	Neurology	Professor, Monash University	Victoria, Australia	Professor Henry Ma is a prominent neurologist with expertise in stroke medicine. He is the Director of Neurology at Monash Health and a Professor of Medicine at Monash University. His research focuses on acute stroke therapy and neuroimaging. Professor Ma has been instrumental in developing stroke services and research programs in Australia. He has contributed to numerous clinical trials and publications in the field of stroke.
Prof. Geoffrey A Donnan (MB BS, MD, FRACP, FRCP (Edin))	Neurology	Professor, University of Melbourne	Victoria, Australia	Professor Geoffrey A. Donnan is a renowned neurologist specializing in stroke research and clinical management. He is a Professor of Neurology at the University of Melbourne and co-chair of the Australian Stroke Alliance. He served as the Director of The Florey Institute of Neuroscience and Mental Health from 2009 to 2018. His research focuses on clinical stroke management, and he co-founded the Australian Stroke Trials Network. Professor Donnan has held leadership roles, including Past President of the World Stroke Organization (2006–2008) and Chair of the World Congress of Neurology (2005). He has received several prestigious awards, such as the William M. Feinberg Award for Excellence in Clinical Stroke (2007) and the World Stroke Organization Leadership Award (2012).

References

- Albers, G. W., Marks, M. P., Christensen, S., Lansberg, M. G., Straka, M., & Bammer, R. (2015).
- American Heart Association. (2023). Stroke research and therapeutic advancements.
- Campbell, B. C., Mitchell, P. J., & Yan, B. (2015). Acute ischemic stroke: Clinical approaches and imaging insights. Brain and Behavior, 5(5), 357–366.
- Campbell, B. C., Mitchell, P. J., & Yan, B. (2015). Neurovascular interventions in ischemic stroke: Review of the evidence for thrombectomy and reperfusion strategies. Lancet Neurology, 14(7), 773–780.
- Campbell, B. C. V., & Desmond, P. M. (2017). Advanced neuroimaging techniques in acute stroke management: The potential role of MRI in identifying salvageable brain tissue. Cerebrovascular Diseases, 44(2), 60–69.
- European Stroke Organisation. (2021). Therapeutic strategies for acute ischemic stroke management.
- Khatri, P., & Lansberg, M. G. (2016). Endovascular thrombectomy for acute ischemic stroke: Current evidence and future directions. Journal of the American College of Cardiology, 67(22), 2720–2732.
- Lansberg, M. G., Albers, G. W., Marks, M. P., Christensen, S., Straka, M., & Bammer, R. (2015). Thrombectomy 6 to 24 hours after stroke with a mismatch between diffusion and perfusion imaging. New England Journal of Medicine, 372(24), 2285–2295.
- Lansberg, M. G., Marks, M. P., Christensen, S., & Albers, G. W. (2015). Neuroimaging of stroke: Insights and advances. Cerebrovascular Diseases, 39(3), 221–229.
- National Institute of Neurological Disorders and Stroke. (2022). Stroke therapeutic research. U.S. Department of Health and Human Services.
- Nogueira, R. G., & Albers, G. W. (2021). Advances in acute ischemic stroke therapy: From thrombolysis to thrombectomy. Current Treatment Options in Neurology, 23(7), 24.
- Powers, W. J., Derdeyn, C. P., Biller, J., & Latchaw, R. E. (2015). 2015 American Heart Association/American Stroke Association guidelines for the early management of patients with acute ischemic stroke. Stroke, 46(7), 1419–1436.
- Saposnik, G., & Kapral, M. K. (2017). Impact of stroke unit care on long-term mortality and morbidity. Stroke, 48(7), 1886–1892.
- Shaltoni, H., Monga, V., & DeSilva, M. (2020). Advances in stroke therapy: Current research and clinical implications. Stroke Research and Treatment, 2020, 1–12.
- Thom, T., Haase, N., Rosamond, W., & Webb, M. (2018). Stroke: Pathophysiology, diagnosis, and management (6th ed.). Elsevier.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com